Divya Monga, MD
Nephrology · Galveston, TXNPI 1912161415
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $443, 4.4 times the $100 reported in 2019. That places this record below the midpoint for nephrology clinicians in TX, where the typical reported total is $1,420.
Across 17 payments — averaging $38.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$144
- Novartis$121
- Idorsia Pharmaceuticals US Inc$120
- Baxter Healthcare$100
- Mallinckrodt Hospital Products Inc.$42
- OPKO Pharmaceuticals, LLC$35
- plus $85 from 4 others
Across 14 payments — averaging $3936.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Baxter Healthcare$46K
- GSK$9K
What the payments were for
- Food & beverage$646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 1 | $144 |
| Novartis | 5 | $121 |
| Idorsia Pharmaceuticals US Inc | 1 | $120 |
| Baxter Healthcare | 2 | $100 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| OPKO Pharmaceuticals, LLC | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Amgen | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$646 in reported general payments places this provider in the 30th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 14 | $14,705 |
| Allopurinol | 40 | $513 |
| Amlodipine Besylate | 59 | $299 |
| Losartan Potassium | 26 | $142 |
| Furosemide | 34 | $137 |
| Lisinopril | 19 | $108 |
| Carvedilol | 19 | $96 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Galveston
- Tina KocharGalveston$272K
- Shikha WadhwaniGalveston$192K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.